relapsing-remitting multiple sclerosis - Wikidata - awgldk - TriplyDB

relapsing-remitting multiple sclerosis

relapsing-remitting multiple sclerosis

http://www.wikidata.org/entity/Q18555066

about

P1050

interferon beta-1b interferon beta-1a teriflunomide dalfampridine Natalizumab Daclizumab methylprednisolone dimethyl fumarate alemtuzumab fingolimod

P2175

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis Dietary habits and selenium, glutathione peroxidase and total antioxidant status in the serum of patients with relapsing-remitting multiple sclerosis Fingolimod for relapsing-remitting multiple sclerosis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis Mycophenolate mofetil for relapsing-remitting multiple sclerosis Daclizumab for relapsing remitting multiple sclerosis Mycophenolate mofetil for relapsing-remitting multiple sclerosis Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis Daclizumab for relapsing remitting multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis Daclizumab for relapsing remitting multiple sclerosis Natalizumab for relapsing remitting multiple sclerosis Fingolimod for relapsing remitting multiple sclerosis Daclizumab for relapsing remitting multiple sclerosis Natalizumab for relapsing remitting multiple sclerosis Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine Natalizumab: A new treatment for relapsing remitting multiple sclerosis Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence Oral disease-modifying agents in relapsing-remitting multiple sclerosis Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Disease-modifying treatments for multiple sclerosis - a review of approved medications Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis Vagomimetic effects of fingolimod: physiology and clinical implications Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis An update on the evidence base for peginterferon β1a in the treatment of relapsing-remitting multiple sclerosis Drug Therapies for Relapsing-Remitting Multiple Sclerosis

P921

Q2715593-cac1ae69-4cd1-14b2-b99c-1e5bd28fc4ab

P1050

Q1851162-38BF1B90-1D29-4BCD-9B74-46B11CD6671A Q2450337-06BFDB2D-9502-432B-86F0-2FC83AD37237 Q3077133-860FE027-3FDB-4028-AE40-CE536BC59FBF Q372539-49C83B46-3EBF-40D2-9016-4114F72418F2 Q386119-9A340253-7F5B-4B40-8F93-52A66CA89B12 Q412920-80902D79-C4B4-415D-A6A9-BAD6E27F9B70 Q417222-2FF0BB74-FD35-415F-BDAE-4C0CCEEBBA15 Q418123-00F93939-3676-44B9-8105-8C24693F5519 Q420164-C2D1F5EE-0851-4CEB-AF6E-5C620E030095 Q425137-F8BF5AC5-1063-4378-A640-AA4921FF6BA6

P2175

Q21135220-FE625125-0E75-4186-9C98-87CA57C93B63 Q21144329-886A4694-4546-44E5-A712-1A16E18CC205 Q21245912-1DBBA3C9-27BD-441F-AF54-936D099B9CA3 Q24185882-CFCBBE3A-BBC8-482B-A7C4-5A2BEACCF877 Q24187126-89BE824A-CFC8-45F3-8A98-B663BCFC0F43 Q24188270-675FF270-73CD-4C2E-B806-7C8A5C6D0274 Q24194800-B0AED5AD-F0BD-425E-8AD6-1D701BAABEB8 Q24197935-EB22C17C-3291-435B-9AB7-6919686B7F22 Q24200496-B6E7CE13-1049-4AD4-85A9-96AA3653A4D9 Q24200517-683B56F2-8D1F-4DD7-9327-2A2BD9F3F82D Q24200823-218361A9-3AC7-4964-A656-A0C5264FE929 Q24201637-C99E9BE3-DA28-4E18-828D-C609E7019267 Q24201928-D51FA8D5-B05D-4A57-B134-7E182AAFDD90 Q24234454-FC16795A-E8BD-4121-935A-5D0652B8D9AF Q24234742-324C92E7-9A3F-4704-A229-7F529D0B1782 Q24234763-2914DFAD-1FFA-4C4D-8EC8-AB948EBF8766 Q24234794-ED65096A-2531-4FAB-9B8E-10E424E4F333 Q24235861-84183240-29C3-4A9A-90AA-A3FEEE68FDE1 Q24236597-F4A90F92-9B8D-4D36-9C74-6280A46EE3DA Q24240947-FD2C932D-B07A-4535-AA48-31F7893E6E8B Q24241982-E09A4C89-AD43-482C-8575-04433A1DBA6C Q24564715-2E7FA7B6-DA2C-4DF3-8AF0-25C549BB1964 Q24597369-4B07408C-0107-4AB4-9AFB-3C908712D752 Q24683014-9F371574-B81D-4659-85A4-8C0D40FF926D Q24800569-424DBEF0-D84D-47B3-BFBC-FEAAAD36926F Q26752466-074444CC-4E34-4211-A56D-B47822165495 Q26771299-5AFBA69C-4F97-418E-BC7B-57655068B22D Q26771635-ECAB5C4A-ED02-41A5-8B92-74041BD33014 Q26773978-3896915B-4F0C-4CF2-8E19-AA3E1DA039AA Q26776234-D1AF842F-7E69-4F29-A136-036073B70E6C Q26777329-BD821045-9213-4187-A3E8-AD17DB8679F2 Q26777686-EB860A22-23DB-4124-AABC-9182C0C887D3 Q26824991-9317E74A-6009-445E-8DD3-9E88740E003B Q26852672-4F2C9205-D8C7-4F09-BE93-EBB6DB421F47 Q27025730-C1134CA8-458F-4A86-AA65-BFE1651BCCB3 Q27693249-1673495B-54FA-4A67-BCEA-70C692629117 Q28070118-5F1FAC55-DB6F-43D3-B854-6C3605E216EB Q28073377-E29FD9E8-8A9E-4A2E-8E2F-F22A6DAC49A9 Q28076879-C8DB657F-FF29-41A6-9FD2-DA9DB3E643D3 Q28077241-255ED0CA-477E-4C57-88C4-A1C4D03A0CCE

P921

relapsing-remitting multiple sclerosis

http://www.wikidata.org/entity/Q18555066

description

Human disease

@en

Krankheit

@de

مرض يصيب الإنسان

@ar

name

relapserande-remitterande multippel sklerose

@nn

relapsing-remitting multiple sclerosis

@en

sclérose en plaques récurrente-rémittente

@fr

type

label

relapserande-remitterande multippel sklerose

@nn

relapsing-remitting multiple sclerosis

@en

sclérose en plaques récurrente-rémittente

@fr

altLabel

Multiple Sclerosis, Relapsing-Remitting

@en

RRMS

@en

RRMS

@nn

Relapsing-remitting MS

@en

relapserande-remitterande MS

@nn

prefLabel

relapserande-remitterande multippel sklerose

@nn

relapsing-remitting multiple sclerosis

@en

sclérose en plaques récurrente-rémittente

@fr

P1417

Q18555066-A8F959E8-ACFF-4074-9133-2E23EC5D04E3

P1995

Q18555066-1DBB8E6A-D92A-4DC7-A1B1-1475A52CF6AB

Q18555066-ACE26F8B-4BF5-4E0A-8654-6EC7793E8F78

P2176

Q18555066-0EE492A7-EAB0-423C-9589-71F6267585A7

Q18555066-15DA8769-6D1A-4147-8DF9-D6F2E8B1F8F1

Q18555066-38C38464-65B2-4BB1-963D-DA7DADBEA86C

Q18555066-3EFCCBB8-DC81-4718-8325-CAFA6CAD8D73

Q18555066-49E6B8DF-5C9B-4119-B8D8-3A6AB2FB87C3

Q18555066-4C8F288B-5B7A-494C-B9C8-34987CE6E9EC

Q18555066-74C525E4-A5A2-429A-BD99-B6FF8E9FF411

Q18555066-8111F7A7-15D4-4C07-AD5C-523EE40AA8F9

Q18555066-82D353A5-2926-4424-8EFD-46EC9C4077D8

Q18555066-CD00872C-9090-424E-85E8-B128AB91D089

P279

Q18555066-E622D5A6-4077-414F-A2BC-7C437470EE17

P2888

Q18555066-07546982-29E0-46F1-BD2A-F8DD536B13CF

Q18555066-2886B86B-2B60-4967-90B9-02A26C12FCC4

P2892

Q18555066-98EBB539-B90D-45BF-BD88-A77116BA2FD8

Q18555066-B11A5167-E1FA-4CE2-ABB9-119ABBA604D8

P31

Q18555066-228EC7F9-9005-482E-A210-476AEA586CF6

P486

Q18555066-FEA7ADC1-4EE8-4064-8BD1-A8E63D848E58

P5270

Q18555066-02AE35A1-C739-44F1-BF55-21C1A9B9B9E8

P672

Q18555066-0642ECF6-49FA-42B2-A5D6-5320E54D290C

Q18555066-4017C489-E83F-4D38-AB87-B8984B37FB5D

Q18555066-DE0CAFBF-8C21-4EB1-A32C-B28B58A44045

P699

Q18555066-1BED8190-0EE0-4A19-A008-35AD2F11A916

Q18555066-B4F73B48-4393-4BD3-9FE1-93E7571FA6BF

P486

P672

C10.114.375.500.600

C10.314.350.500.600

C20.111.258.250.500.600

P1417

topic/relapsing-remitting-multiple-sclerosis

http://www.w3.org/2001/XMLSchema#string

P1995

P2176

interferon beta-1b

interferon beta-1a

methylprednisolone

dimethyl fumarate

P279

multiple sclerosis

P2888

P2892

C0751967

http://www.w3.org/2001/XMLSchema#string

P31

P486

D020529

http://www.w3.org/2001/XMLSchema#string

P5270

MONDO:0005314

http://www.w3.org/2001/XMLSchema#string

P672

C10.114.375.500.600

http://www.w3.org/2001/XMLSchema#string

C10.314.350.500.600

http://www.w3.org/2001/XMLSchema#string

C20.111.258.250.500.600

http://www.w3.org/2001/XMLSchema#string

P699

DOID:2378

http://www.w3.org/2001/XMLSchema#string